CD34+ antigen expression relating to prognosis in acute myeloid leukemia.
- Author:
Ling LI
1
;
Rui WANG
;
Di ZHONG
;
Bin-Zao WEN
;
Dilinazi ABULAITI
;
Zhi-Qiang LIN
;
Ming JIA
;
Jian-Ping HAO
;
Rong CHEN
;
Xin-Hong GUO
;
Lei WANG
Author Information
1. Department of Hematology, The First Affiliated Hospital, Xinjiang Medical University, Urumqi 830054, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Antigens, CD34;
biosynthesis;
Antigens, CD7;
biosynthesis;
Female;
Fluorescent Antibody Technique, Indirect;
Humans;
Leukemia, Monocytic, Acute;
metabolism;
pathology;
Leukemia, Myeloid, Acute;
metabolism;
pathology;
Leukemia, Myelomonocytic, Acute;
metabolism;
pathology;
Male;
Middle Aged;
Prognosis
- From:
Journal of Experimental Hematology
2005;13(5):812-814
- CountryChina
- Language:Chinese
-
Abstract:
To explore CD34(+) antigen expression in new diagnosed acute myeloid leukemia (AML) and analyze the prognosis for CD34(+) AML patients, the expression of antigen CD34 in 238 AML patients was detected by indirect immunofluorescence assay. The results showed that CD34 in 92 out of the 238 patients (38.7%) were positive, there was relationship between the CD34(+) expression and FAB subtypes (M(0), M(1)), and no CD34(+) expression was observed in M(3) subtypes. The complete remission rate of CD34(+) AML patients was 32%, which was lower than that of CD34(-) AML (61%). The lymphoid-associated antigen (CD7) was significantly increased in CD34(+) AML patients, compared with CD34(-) patients (P < 0.05). It is concluded that CD34(+) AML patients show poor prognosis and lower CR rate. The detection of CD34 expression is of some value in predicting prognosis in AML.
